Roche Holding, CH1499059983

Roche Holding stock gets FDA approval for Wilserdly breast pill

Published on 11/17/2026 at 11:17 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Roche Holding stock gains a new oncology catalyst as Wilserdly wins US approval for advanced breast cancer. A broader decision is due by November 30.

FDA approval opens a new oncology opportunity

  • Wilserdly received US approval with everolimus for a defined group of patients with advanced breast cancer.
  • The evERA study showed a 62 percent reduction in the risk of disease progression or death versus standard endocrine therapy with everolimus.
  • The FDA is expected to decide by November 30 on an additional early-stage breast cancer indication.
Roche Holding, CH1499059983, Illustration mit AI erstellt.

Roche said on Monday, November 16, that the U.S. Food and Drug Administration approved Wilserdly, also known as giredestrant, in combination with everolimus for a defined group of adults with advanced breast cancer. The approval covers estrogen receptor-positive, HER2-negative, ESR1-mutated locally advanced or metastatic disease detected by an FDA-authorized test, after recurrence following adjuvant endocrine therapy or progression on at least one endocrine-based metastatic regimen. Roche published the announcement in its FDA approval release.

Roche Holding stock traded at 442.48 euros on Lang & Schwarz at 11:10 CET on Tuesday, November 17.

Study results underpin the approval

The decision was supported by the phase III evERA Breast Cancer study. In patients whose ESR1-mutated tumors had progressed after treatment with a CDK4/6 inhibitor, Wilserdly plus everolimus reduced the risk of disease progression or death by 62 percent compared with standard endocrine therapy plus everolimus. Roche reported a stratified hazard ratio of 0.38, with a 95 percent confidence interval of 0.27 to 0.54 and a p-value below 0.0001.

The company said the combination prolonged progression-free survival in the study population. Roche's release describes Wilserdly as an oral selective estrogen receptor degrader designed to inhibit estrogen-receptor signaling. Combined with everolimus, it targets a second pathway involved in endocrine resistance. The fully oral regimen also avoids injections, according to Roche Chief Medical Officer Levi Garraway.

Next decision could widen the market

Roche is seeking a second U.S. indication for Wilserdly as an adjuvant treatment for adults with ER-positive, HER2-negative stage I, II and III breast cancer at intermediate to high risk of recurrence. The FDA accepted that application for Priority Review and set a Prescription Drug User Fee Act date of November 30, 2026. Approval in that setting would extend the medicine from advanced disease into earlier-stage treatment.

The current approval gives Roche a commercial entry point while its broader development program remains active. The company says its Wilserdly program includes six company-sponsored phase III studies across different treatment settings and lines of therapy. The regulatory outcome and the pending adjuvant decision are therefore key milestones for the group's breast-cancer franchise.

Roche Holding at a glance

  • Company: Roche Holding AG
  • ISIN: CH1499059983
  • Lang & Schwarz quote: 442.48 euros, Tuesday, November 17, 2026, 11:10 CET
  • Regulatory event: U.S. FDA approval of Wilserdly on November 16, 2026

The Swiss market backdrop can be followed via the SMI.

More news and analyses on Roche Holding stock

Disclaimer...
en | CH1499059983 | ROCHE HOLDING | boerse | 70526040 | bgmi